- Home
- MUA vs URGN Comparison
MUA vs URGN Comparison
Compare MUA & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MUA
- URGN
- Stock Information
- Founded
- MUA 1993
- URGN 2004
- Country
- MUA United States
- URGN United States
- Employees
- MUA N/A
- URGN N/A
- Industry
- MUA Investment Bankers/Brokers/Service
- URGN Biotechnology: Pharmaceutical Preparations
- Sector
- MUA Finance
- URGN Health Care
- Exchange
- MUA Nasdaq
- URGN Nasdaq
- Market Cap
- MUA 396.8M
- URGN 463.2M
- IPO Year
- MUA N/A
- URGN 2017
- Fundamental
- Price
- MUA $10.29
- URGN $4.24
- Analyst Decision
- MUA
- URGN Strong Buy
- Analyst Count
- MUA 0
- URGN 8
- Target Price
- MUA N/A
- URGN $27.92
- AVG Volume (30 Days)
- MUA 92.6K
- URGN 2.4M
- Earning Date
- MUA 01-01-0001
- URGN 05-12-2025
- Dividend Yield
- MUA 4.84%
- URGN N/A
- EPS Growth
- MUA N/A
- URGN N/A
- EPS
- MUA N/A
- URGN N/A
- Revenue
- MUA N/A
- URGN $91,871,000.00
- Revenue This Year
- MUA N/A
- URGN $35.06
- Revenue Next Year
- MUA N/A
- URGN $112.94
- P/E Ratio
- MUA N/A
- URGN N/A
- Revenue Growth
- MUA N/A
- URGN 8.98
- 52 Week Low
- MUA $8.61
- URGN $3.42
- 52 Week High
- MUA $11.43
- URGN $20.70
- Technical
- Relative Strength Index (RSI)
- MUA 47.77
- URGN 27.72
- Support Level
- MUA $10.20
- URGN $3.71
- Resistance Level
- MUA $10.54
- URGN $4.25
- Average True Range (ATR)
- MUA 0.11
- URGN 0.91
- MACD
- MUA -0.00
- URGN -0.45
- Stochastic Oscillator
- MUA 35.71
- URGN 9.87
About MUA Blackrock MuniAssets Fund Inc
Blackrock Muniassets Fund Inc is a closed-end fund. Its objective is to provide high current income exempt from U.S. federal income taxes by investing in a portfolio of medium- to lower-grade or unrated municipal obligations.
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.